Inhibition of cytomegalovirus late antigen expression and cytomegalovirus replication in human fibroblasts and differentiated monocytic cells by liposome-encapsulated foscarnet

This publication has 18 references indexed in Scilit:

• Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution, and pharmacokinetics
  AIDS, 1995
• Liposomes as delivery systems in the prevention and treatment of infectious diseases
  Pharmacy World & Science, 1995
• The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cellsin vitro: The role of calcium and iron
  Calcified Tissue International, 1993
• Mortality in Patients with the Acquired Immunodeficiency Syndrome Treated with either Foscarnet or Ganciclovir for Cytomegalovirus Retinitis
  New England Journal of Medicine, 1992
• Antiviral Activity and Pharmacokinetics of Liposome-Encapsulated Phosphonoformate in Rauscher Murine Leukemia Virus-Infected Mice
  Journal of Liposome Research, 1992
• Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells
  Archives of Virology, 1991
• Foscarnet Nephrotoxicity: Mechanism, Incidence and Prevention
  American Journal of Nephrology, 1989
• 5‐Fluoroorotate: a new liposome‐dependent cytotoxic agent
  FEBS Letters, 1985
• The acid-catalysed decarboxylation of phosphonoformic acid
  Journal of the Chemical Society B: Physical Organic, 1971
• A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
  Canadian Journal of Biochemistry and Physiology, 1959